Healthcare
Prosthetic Heart Valve Market Size Forecast to Reach $7.61 Billion by 2025
Prosthetic Heart Valve Market size is forecast to reach $7.61 billion by 2025, growing at a CAGR of 9.4% during the forecast period 2020-2025. A prosthetic heart valve is a one-way valve implanted into the heart of a patient to replace a dysfunctional native heart valve. In practice, ideal valve substitute does not exist, and each of the currently available prosthetic valves has inherent limitations. Three basic types of mechanical heart valve design exist, they are bileaflet, monoleaflet, and caged ball valves. The left-sided valves, the aortic valve and the mitral valve have a higher predisposition to disease compared to their right-sided counterparts. Growing geriatric population, increasing prevalence of heart valve disease (HVD), regulatory approvals for advanced new procedures, increasing government funding for advanced researches and favorable reimbursement policies for prosthetic heart valve are driving the market growth in recent years. In addition, major market development of key players like Abott Laboratories, Medtronic PLC and Boston Corporation are additional factors driving the growth of the market.
Key Takeaways
- North America dominated the Prosthetic Heart Valve Market in the year 2019 owing to increasing technological advancements and increasing heart valve disorders among the growing geriatric population. The Prosthetic Heart Valve Market scope for different regions will be provided in the final report.
- Growing geriatric population, increasing prevalence of heart valve disease, regulatory approvals for advanced new procedures, increasing government funding for advanced researches and favorable reimbursement policies for prosthetic heart valve is estimated to drive the industry growth during the forecast period 2020-2025.
- Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Prosthetic Heart Valve Market Report.
- High cost of heart operation resulting in lower reach to the people is anticipated to hamper the market growth of the Prosthetic Heart Valve Industry.
- Increasing prevalence of heart valve disease
- Favorable reimbursement policies for prosthetic heart valve
- High cost of heart operation resulting in lower reach to people
- In January 2020, Abott announced that its Tendyne Transcatheter Mitral Valve Implantation (TMVI) system received CE Mark and is approved for use in Europe.
- In September 2019, Medtronic PLC announces FDA approval and U.S. launch of next-generation Evolut PRO+ TAVR System for treatment of symptomatic severe aortic stenosis patients.
- In April 2019, Boston announced that it had received U.S. FDA approval for the LOTUS Edge Aortic Valve System.






